U
OMED

UBS’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

UBS’s Portfolio OMED Stock Details OMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$62K Sell
3,297
-413
-11% -$8.3K ﹤0.01% 6577
2014
Q2 		$87K Sell
3,710
-100
-3% -$2.47K ﹤0.01% 6117
2014
Q1 		$128K Buy
3,810
+2,059
+118% +$69.4K ﹤0.01% 5706
2013
Q4 		$52K Buy
1,751
+641
+58% +$11.7K ﹤0.01% 6927
2013
Q3 		$17K Buy
+1,110
New +$20.6K ﹤0.01% 8290

Other funds holding OMED

SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

UBS's OMED Position: Q3 2014 in Review

UBS reduced its OncoMed Pharmaceuticals, Inc. (OMED) stake by 11% in Q3 2014, selling an estimated $8.3K and leaving 3,297 shares worth $62K. The position accounts for ﹤0.01% of the portfolio, ranked #6577.

UBS first reported a position in OMED in Q3 2013 and has held it in 5 quarters since. The position peaked at $128K in Q1 2014. 62 funds tracked by Wall St. Rank hold OMED as of Q3 2014.

  • UBS held 3,297 shares of OncoMed Pharmaceuticals, Inc. worth $62K as of Q3 2014.
  • UBS sold 413 OncoMed Pharmaceuticals, Inc. shares in Q3 2014, an estimated $8.3K.
  • OncoMed Pharmaceuticals, Inc. made up ﹤0.01% of UBS's portfolio in Q3 2014, its #6577 holding.
  • UBS first reported a position in OncoMed Pharmaceuticals, Inc. in Q3 2013 and has held it in 5 quarters since.
  • UBS's OncoMed Pharmaceuticals, Inc. position peaked at $128K in Q1 2014.
  • 62 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.